Search Bar & Filters
Found 6 Actively Recruiting clinical trials
Actively Recruiting
Healthy Volunteer
Researchers are evaluating the safety and immune response of an investigational yellow fever vaccine called vYF in young children aged 9 months to 5 years. This Phase III study compares vYF with two licensed yellow fever vaccines, Stamaril and YF-VAX, including when vYF is given alongside the measles, mumps, and rubella MMR vaccine in infants aged 11 to 15 months. The study aims to see if vYF can safely help the body develop protective antibodies against yellow fever. Participants will be randomized into groups by age to receive one dose of either vYF, Stamaril, or YF-VAX vaccine. A special group of infants aged 11 to 15 months will receive vYF together with the MMR vaccine in one visit. A subset of children aged 9 to 24 months will be invited to receive a booster dose of the yellow fever vaccine three years after the initial vaccination. The booster is not offered to the group receiving the combined vYF and MMR vaccine. Participants will be involved for about three years, with some in the booster group followed for an additional six months. The study includes multiple blood tests to measure immune response at several time points, starting from the day of vaccination and continuing annually up to three years. Safety is monitored closely through reports of side effects and laboratory tests. The main outcome is the percentage of participants developing antibodies against yellow fever 28 days after vaccination.
Actively Recruiting
Healthy Volunteer
This research aims to evaluate the immune response and safety of an investigational chickenpox vaccine VNS Vaccine compared to an already approved vaccine called Varivax VV. The study focuses on healthy children who have not previously had chickenpox or received a chickenpox vaccine, and takes place when the second dose is given three months after the first dose, which is administered between 12 and 15 months of age. Participants are randomly assigned to one of three groups one group receives two doses of the Varivax vaccine another group receives two doses of the investigational VNS vaccine and the third group receives a first dose of Varivax followed by a second dose of the VNS vaccine. Additional vaccines including measles, mumps, and rubella MMR, hepatitis A HAV, and pneumococcal conjugate vaccine PCV are given on the first day. In some countries, a second dose of MMR is also given between 15 and 18 months according to national guidelines. During the study, researchers will monitor immune responses by measuring specific antibodies against the chickenpox virus after the second dose, particularly 43 days post-vaccination. They will also track any local or systemic side effects following each vaccine dose, recording adverse events up to nearly nine months after the first dose. The total participation includes multiple visits over this time, ensuring detailed safety and immune response assessment for each child.
Actively Recruiting
Cancer is a major cause of illness and death among children, adolescents, and young adults CAYAs, particularly in low- and middle-income countries LMICs where access to timely diagnosis and treatment is often limited. This prospective, multicenter observational study follows CAYAs with cancer receiving routine care at participating hospitals in LMICs, aiming to better understand treatment outcomes and challenges faced by patients and families. Participants receive standard medical care as provided by their local hospitals without experimental treatments or changes to their treatment plans. The study observes a single group of patients over time to collect information from medical records and questionnaires focusing on access to care and social factors impacting treatment. The study covers a follow-up period extending up to 36 months after enrollment. During the study, researchers will gather data on clinical outcomes, treatment complications, interruptions, and social factors affecting care. Data collection includes medical record reviews and patient or family questionnaires. The study aims to provide valuable information to help improve cancer care and outcomes in resource-limited settings, with total participant engagement lasting up to three years.
Actively Recruiting
This research aims to evaluate cancer treatment outcomes among children, adolescents, and young adults aged 0 to 21 years living in low- and middle-income countries LMICs. It focuses on acute lymphoblastic leukemia ALL and lymphoblastic lymphoma LBL, conditions where treatment success varies widely between high-income and LMICs due to factors like delayed diagnosis and limited access to quality care. The study seeks to inform future efforts to improve cancer care and reduce treatment failures in these regions. The study involves a retrospective review of medical records from participating oncology centers in countries including Guatemala, Honduras, El Salvador, Armenia, and Tanzania. It includes patients with any type of cancer diagnosis who received substantial anti-cancer treatment such as chemotherapy, surgery, radiation, or immunotherapy. Special attention is given to patients with ALL or LBL to assess therapy-related toxicities and treatment outcomes over a three-year follow-up period. Participants medical records will be analyzed to estimate the incidence of treatment failure, including relapse or progression, and therapy-related severe toxicities. Data on event-free survival and overall survival will also be collected. No experimental treatments are administered, as this is a purely observational study. The study period covers up to three years from each patients cancer diagnosis, using existing health data to better understand treatment challenges and outcomes in LMICs.
Actively Recruiting
Healthy Volunteer
Researchers are evaluating three lots of an investigational 21-valent pneumococcal conjugate vaccine PCV21 to see if they produce similar immune responses and are safe compared to a licensed 20-valent pneumococcal vaccine 20vPCV in healthy infants aged approximately 2 months. This phase 3, randomized, modified double-blind study aims to measure antibody development and safety of these vaccines as part of routine pediatric immunization. Participants will receive four doses of either one of three PCV21 vaccine lots or the 20vPCV comparator at about 2, 4, 6, and 12 months of age through intramuscular injections. The study includes two cohorts Cohort A, which is randomized to three PCV21 groups or one 20vPCV group, and Cohort B, randomized to three PCV21 groups only. All vaccinations are co-administered with routine pediatric vaccines as per local recommendations. Throughout the study, participants will attend six visits spaced over approximately 17 months. Researchers will collect blood samples to measure immune response 30 days after the third vaccine dose and monitor immediate and longer-term adverse events after each injection. Safety and immunogenicity are assessed through questionnaires, medical evaluations, and lab tests, with monitoring continuing up to six months after the final vaccine dose.
Actively Recruiting
Healthy Volunteer
This research aims to evaluate the safety and immune response of an investigational varicella vaccine called NBP608 in healthy children aged 12 months to 12 years. The study compares NBP608 with licensed varicella vaccines to understand how well it works and how safe it is. This Phase III, randomized, double-blinded, multinational study involves children from multiple centers. Participants will be randomly assigned to receive either one of two potencies of NBP608 or one of two licensed varicella vaccines. Each participant will receive one or two subcutaneous injections of the study vaccine. The study includes a two-dose regimen, and the vaccines are administered via injections under the skin. The study period lasts about 15 months, during which participants will have seven clinic visits and follow-up phone calls after each vaccination to monitor safety. Throughout the study, researchers will collect blood samples at set times to measure immune response to the varicella virus. Safety is monitored by tracking adverse events, serious adverse events, and special interest events after vaccination. Participants and their parents or guardians will attend scheduled visits and receive follow-up calls to report any side effects. The main outcomes measured include rates of immune response and antibody levels six weeks after each dose and six months after the second dose.